Observational {{label}}

Prognostic Value of a Diaphragmatic Endurance Test in Patients With Amyotrophic Lateral Sclerosis


Overview

{{trial.Sponsor}} {{trial.Sponsor}}
{{route.Name}}
{{route.Name}}
Approved by FDA
Approved outside USA
Is a supplement

Details

Enrollment Criteria

{{m.Name}}
{{trial.ExternalId}} (First Published: {{trial.FirstPublishedDate|date}} on {{trial.SourceName}})
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease which involves respiratory muscles and can lead at short term to respiratory failure. The occurrence of respiratory failure is associated with morbidity and an increased mortality. To date, respiratory muscle weakness is predicted from the reduction of vital capacity, maximal inspiratory force, nocturnal symptoms and hypercapnia. Even taken together, the predictive value of these indices is low. The investigators hypothesize that an endurance test of diaphragmatic work would be more sensitive to respiratory muscle involvement than maximal respiratory force. Consequently, the investigators assessed diaphragmatic performance through an isocapnic hyperventilation test (IHT) in patients at the onset of ALS and, then regularly up to the occurrence of respiratory failure. The investigators make the hypothesis that IHT will be altered earlier than maximal inspiratory force

Inclusion Criteria for Patients :
- Older than 18 years old and younger than 80 years old
- ALS patient seen during the diagnostic assessment
Inclusion Criteria for control group :
- Older than 25 years old and younger than 80 years old
- No respiratory or neurologic active pathology
Exclusion Criteria for Patients :
- Bulbar ALS (inability to perform maximal respiratory maneuvers)
- Dementia
- Respiratory failure at diagnosis (arterial carbon dioxide partial pressure (pCO2) > 45
mmHg)
- Respiratory or neurologic active pathology
Exclusion Criteria for control group :
- Chest wall deformation with spirometric defect

Locations
{{countryGroup}}
{{regionGroup}}
{{location.Facility}}
{{location.City !== '' ? location.City + ',' : ''}} {{location.RegionAbbreviation}} {{location.PostalCode}} {{location.Country}}
{{location.Facility !== '' ? location.Facility + ',' : ''}} {{location.City !== '' ? location.City + ',' : ''}} {{location.RegionAbbreviation}} {{location.PostalCode}} {{location.Country}}
Location Contact: {{location.Contact.Name}} {{location.Contact.Name}} Phone: {{location.Contact.Phone}}
Join the ALS Research Collaborative (ARC) Study Today!
Ready to make a difference in ALS research?
Join the ARC Study! Whether you're living with ALS or an asymptomatic gene carrier, your participation can help inform ALS research and lead to new treatments.
ALS Research Collaborative
Thank You to Our Sponsors
Mitsubishi Tanabe Pharma